

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)



(10) International Publication Number
WO 2023/220408 A1

(51) International Patent Classification:

C07D 401/06 (2006.01) A61P 25/28 (2006.01)
C07D 401/12 (2006.01) A61K 31/506 (2006.01)
C07D 403/12 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/022097

(22) International Filing Date:

12 May 2023 (12.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/341,975 13 May 2022 (13.05.2022) US

(71) Applicant: NEUMORA THERAPEUTICS, INC.

[US/US]; 65 Grove Street, Suite 102, Watertown, Massachusetts 02472 (US).

(72) Inventors: BEAUSOLEIL, Anne-Marie; c/o Neumora

Therapeutics, Inc., 65 Grove Street, Suite 102, Watertown, Massachusetts 02472 (US). HUDSON, Ryan; c/o Neumora Therapeutics, Inc., 65 Grove Street, Suite 102, Watertown, Massachusetts 02472 (US).

(74) Agent: HERMANN, Karl R. et al.; Seed Intellectual

Property Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle, Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,


Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2023/220408 A1

(54) Title: MODULATORS OF NLRP3 INFLAMMASOME AND RELATED PRODUCTS AND METHODS



(57) Abstract: Compounds are provided for modulating NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein X, R¹, R², R³, R⁴, R⁵, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, and n are as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.